Serotonin level in biological fluids as a marker of neuroorthopedic diseases diagnostics and treatment efficiency [PDF]
, 2021 This article discusses the issues of studying the dynamics of changes in serotonin in biological fluids as a marker in various neuro-orthopedic diseases in patients of different ages. For this, an analysis of clinical practice has been carried out. It is
M. E. Winderlich, N. B. Shchekolova
core +2 more sources
Усовершенствование метода определения ДНК-азной активности [PDF]
, 2013 плазмаферментные ...
Генералова, А. Г. +2 more
core +3 more sources
Selective serotonin reuptake inhibitors and spermatogenesis [PDF]
, 2021 Introduction. According to the WHO data, depression is a common disease among women and men of reproductive age. One line of the correction of depressive disorders is selective serotonin reuptake inhibitors (SSRIs).
E. S. Korshunova +3 more
core +2 more sources
The new molecular targets for antidepressants [PDF]
, 2021 The efficacy of depressive disorders treatment is insufficient. It is explained by an incomplete understanding of both pathogenesis of depression and antidepressants mechanism action.
D. V. Evdokimov +2 more
core +2 more sources
Drug-induced intracerebral hemorrhage [PDF]
, 2022 Intracerebral hemorrhage (ICH), which is a form of hemorrhagic stroke, is an extremely serious disease. This pathology is characterized by very high levels of disability and mortality.
A. I. Kochetkov +3 more
core +2 more sources
Antidepressants are selective serotonin neuronal reuptake inhibitors: 40-year history [PDF]
, 2015 The paper presents historical prerequisites for designing antidepressants from a group of selective serotonin neuronal reuptake inhibitors (SSRIs): to determine a lower serotonin concentration in the different tissues of depressed patients; to establish ...
D. S. Danilov
core +2 more sources
The rationale for antidepressants in the treatment of schizophrenia: A modern view on the problem in the context of evidence-based medicine [PDF]
, 2016 The paper discusses whether antidepressant treatment is rational in schizophrenics. It analyzes the results from trials evaluating the efficiency of the therapy in patients with depressive, negative, or obsessive-phobic symptoms.
D. O. Magomedova +2 more
core +2 more sources
Фармакодинамический потенциал комбинаций атипичного антидепрессанта миансерина с селективными ингибиторами обратного захвата серотонина [PDF]
, 2012 антидепрессантымиансеринсертраминпараксетинфлувоксаминсеротони
Бизунок, Н. А. +1 more
core
Фармакодинамический потенциал комбинаций венлафаксина с селективными ингибиторами обратного захвата серотонина [PDF]
, 2012 фармакодинамикавенлафаксинсеротонина захвата ...
Бизунок, Н. А. +1 more
core
Безопасность лекарственных средств [PDF]
, 2012 ингибиторылекарств мониторингзивокслинезолидлекарствалекарств ...
Сеткина, С. Б.
core